Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Frost

Showing results (291-300 of 300) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 300 results.
Annals of Neurology|August 28, 2023
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT TrialElizabeth Martina Bebin, Jurriaan M Peters, Brenda E Porter, et al.
JCI Insight|February 28, 2020
FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosisJack Leslie, Ben Jm Millar, Alicia Del Carpio Pons, et al.
Pediatric Neurology|August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) TrialLaura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2000
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeysD H Barouch, A Craiu, M J Kuroda, et al.
Pediatric Neurology|October 8, 2025
Neurodevelopmental Outcomes From the PREVeNT TrialSarah E O'Kelley, Jamie K Capal, Tarrant O McPherson, et al.
Pediatric Neurology|March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT StudyTarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Pediatric Neurology|August 16, 2021
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management RecommendationsHope Northrup, Mary E Aronow, E Martina Bebin, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 30

Showing results (291-300 of 300) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 300 results.
Annals of Neurology|August 28, 2023
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT TrialElizabeth Martina Bebin, Jurriaan M Peters, Brenda E Porter, et al.
JCI Insight|February 28, 2020
FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosisJack Leslie, Ben Jm Millar, Alicia Del Carpio Pons, et al.
Pediatric Neurology|August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) TrialLaura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2000
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeysD H Barouch, A Craiu, M J Kuroda, et al.
Pediatric Neurology|October 8, 2025
Neurodevelopmental Outcomes From the PREVeNT TrialSarah E O'Kelley, Jamie K Capal, Tarrant O McPherson, et al.
Pediatric Neurology|March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT StudyTarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Pediatric Neurology|August 16, 2021
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management RecommendationsHope Northrup, Mary E Aronow, E Martina Bebin, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 30